San Miguel Hospital Corporation
San Miguel Hospital Corporation was paid $13.21M by Medicaid between Jan 2018 and Oct 2023, across 157 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
LAS VEGAS, NM 87701
Next to other General Acute Care Hospital providers in New Mexico
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 62,523 | $3.09M | |
| 2019 | 42,199 | $2.21M | |
| 2020 | 29,480 | $1.69M | |
| 2021 | 32,007 | $2.03M | |
| 2022 | 36,099 | $2.36M | |
| 2023 | 30,377 | $1.83M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 15,010 | 14,114 | $2.94M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 14,886 | 14,255 | $2.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 7,342 | 6,843 | $1.90M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 2,664 | 2,506 | $402K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.0% | 8,655 | 7,661 | $393K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.8% | 5,075 | 4,303 | $373K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.6% | 5,014 | 4,735 | $348K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 1,807 | 1,724 | $338K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.5% | 6,449 | 5,954 | $325K |
| 87631 | 2.4% | 3,862 | 3,675 | $321K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 2,946 | 2,874 | $267K |
| 80053 | Comprehensive metabolic panel | 1.9% | 19,102 | 16,829 | $247K |
145 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 862 | $244K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 3,107 | $217K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 7,229 | $209K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 5,308 | $206K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 20,586 | $142K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.0% | 5,846 | $138K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,381 | $125K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,359 | $124K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,955 | $124K |
| G0378 | Hospital observation service, per hour | <1% | 375 | $124K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,170 | $106K |
| 71250 | <1% | 788 | $94K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 503 | $85K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 231 | $65K |
| 73610 | <1% | 726 | $55K | |
| 84484 | <1% | 6,053 | $52K | |
| 73030 | <1% | 695 | $48K | |
| 81001 | <1% | 10,260 | $47K | |
| 73562 | <1% | 616 | $44K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 818 | $44K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 550 | $43K |
| 83690 | <1% | 3,499 | $39K | |
| 73130 | <1% | 702 | $39K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,426 | $34K |
| 72100 | <1% | 468 | $34K | |
| 83880 | <1% | 1,781 | $34K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 744 | $34K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,721 | $32K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,962 | $31K |
| 0002A | <1% | 768 | $29K | |
| 73110 | <1% | 514 | $28K | |
| 73630 | <1% | 497 | $26K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 808 | $24K |
| 87081 | <1% | 1,968 | $24K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 165 | $24K |
| 70486 | <1% | 125 | $19K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 814 | $19K |
| 87040 | <1% | 1,999 | $19K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,103 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,475 | $19K |
| 0001A | <1% | 706 | $17K | |
| 84703 | <1% | 2,216 | $16K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,054 | $16K |
| 83605 | <1% | 1,457 | $13K | |
| 85610 | <1% | 3,454 | $12K | |
| 82550 | <1% | 1,820 | $12K | |
| 82553 | <1% | 1,105 | $12K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 128 | $11K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 39 | $9K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 794 | $9K |
| 82962 | <1% | 1,380 | $9K | |
| 74018 | <1% | 191 | $9K | |
| 86140 | <1% | 951 | $8K | |
| 83735 | <1% | 865 | $8K | |
| 87077 | <1% | 580 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 405 | $6K |
| 73560 | <1% | 130 | $6K | |
| 87490 | <1% | 233 | $6K | |
| 59025 | Fetal non-stress test | <1% | 66 | $6K |
| 87186 | <1% | 559 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 68 | $5K |
| 87420 | <1% | 203 | $5K | |
| 87590 | <1% | 233 | $5K | |
| 80320 | <1% | 145 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 369 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 781 | $5K |
| 85027 | <1% | 782 | $4K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 374 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 50 | $4K |
| 73502 | <1% | 98 | $4K | |
| 80061 | Lipid panel | <1% | 283 | $4K |
| 86850 | <1% | 306 | $4K | |
| 85379 | <1% | 488 | $4K | |
| 84702 | <1% | 180 | $4K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 44 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $3K |
| 82150 | <1% | 392 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 109 | $3K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 27 | $3K |
| 85730 | <1% | 494 | $2K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 12 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 137 | $2K |
| 80179 | <1% | 63 | $2K | |
| 80143 | <1% | 63 | $2K | |
| 93971 | <1% | 41 | $2K | |
| 86901 | <1% | 355 | $2K | |
| 73080 | <1% | 42 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 124 | $2K |
| 86900 | <1% | 322 | $2K | |
| 87070 | <1% | 175 | $2K | |
| 90715 | <1% | 53 | $2K | |
| G0435 | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening | <1% | 133 | $2K |
| 97161 | <1% | 70 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 86 | $1K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 50 | $1K |
| 96367 | <1% | 46 | $1K | |
| 73140 | <1% | 27 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,980 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 365 | $1K |
| 76770 | <1% | 17 | $1K | |
| 87205 | <1% | 138 | $1K | |
| 73090 | <1% | 26 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,817 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,450 | $1K |
| 12002 | <1% | 17 | $1K | |
| 72050 | <1% | 12 | $1K | |
| 86592 | <1% | 180 | $1K | |
| 72170 | <1% | 16 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 143 | $924.24 |
| 97010 | <1% | 48 | $832.91 | |
| 51702 | <1% | 24 | $764.63 | |
| 81003 | <1% | 207 | $678.72 | |
| 72070 | <1% | 12 | $663.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $609.40 |
| 94760 | <1% | 89 | $604.25 | |
| 82140 | <1% | 48 | $594.48 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 808 | $576.56 |
| 73590 | <1% | 14 | $567.59 | |
| 96376 | <1% | 581 | $538.63 | |
| 87340 | <1% | 42 | $533.37 | |
| 82803 | <1% | 23 | $493.02 | |
| 86762 | <1% | 28 | $364.71 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $336.40 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $336.40 |
| 87075 | <1% | 32 | $310.80 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 125 | $263.84 |
| 36600 | <1% | 17 | $234.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 61 | $205.85 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 205 | $195.63 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 177 | $181.31 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 189 | $141.96 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 44 | $133.69 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 104 | $104.41 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 199 | $80.03 |
| 82950 | <1% | 12 | $79.07 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 25 | $77.04 |
| 85652 | <1% | 31 | $71.99 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 12 | $61.70 |
| 81002 | <1% | 14 | $50.59 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 78 | $24.35 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 49 | $23.18 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 32 | $4.97 |
| 94761 | 0% | 236 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 46 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 737 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Jackson Hospital Corporation | Jackson, KY | $34.90M |
| Deming Hospital Corporation | Deming, NM | $34.61M |
| Hospital of Louisa, INC. | Louisa, KY | $27.77M |
| Hospital of Barstow INC | Barstow, CA | $16.88M |
| Paintsville Hospital Company, LLC | Paintsville, KY | $15.46M |
| Tooele Hospital Corporation | Tooele, UT | $11.66M |
| Forrest City Arkansas Hospital Company LLC | Forrest City, AR | $7.42M |
| MMC of Nevada LLC | Mesquite, NV | $2.60M |
| Fort Payne Hospital Corporation | Fort Payne, AL | $2.60M |
| Williamston Hospital Corporation | Williamston, NC | $2.31M |
| Waukegan Illinois Hospital Company LLC | Waukegan, IL | $2.30M |
| Southwest Kidney Institute Vascular Center LLC | Tempe, AZ | $850K |
| Evanston Hospital Corporation | Evanston, WY | $378K |
| Marion Hospital Corporation | Marion, IL | $220K |
| Anna Hospital Corporation | Anna, IL | $217K |
| National Healthcare of MT Vernon INC | Mount Vernon, IL | $158K |
| Red Bud Illinois Hospital Company LLC | Red Bud, IL | $36K |
| Tooele Hospital Corporation | Tooele, UT | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.